The month ahead: September’s upcoming events
It’s back to school for biotech, with a packed conference schedule.
It’s back to school for biotech, with a packed conference schedule.
The biotech gives up on the exon 20 market, and says Tagrisso’s initial setting is no longer meaningful in the west.
But Repare and Black Diamond still have rebuilding to do.
First data with the biotech’s new EGFR project prompts a 236% share price bump.